Novartis Investigative Site

Bunkyō-ku, Tokyo 113-8677

0 studies enrolling now · 1 studies all time

What they study most

Graft-versus-host Disease (GVHD)

Studies at this site

• A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3) — Completed